Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy

Authors: Drevs J.; Medinger M.; Schmidt-Gersbach C.; Weber R.; Unger C.

Source: Current Drug Targets, Volume 4, Number 2, February 2003 , pp. 113-121(9)

Publisher: Bentham Science Publishers

Abstract:

Because conventional chemotherapy is not specific for cancer cells leading to toxic side effects there is a need for novel agents with high grade antitumor specificity. The major prerequisite to develop such drugs is to understand the targets that these agents should attack. In recent years a number of promising new anticancer drugs have been developed which target intracellular pathways or extracellular cell molecules. The clinically most effective compounds function as tyrosine kinase inhibitors. In the past, various tyrosine kinase receptors have been identified as regulators of tumor or tumor vessel growth. Having shown their expression characteristics in different tumor entities, specific inhibitors of the ATP binding sites of these receptors or antibodies were developed and entered clinical trials. The pathognomonic role of the tyrosine kinase defines the way of action of the inhibiting drug, whereas the amount of expression in tumor tissue defines the rationale to use the inhibitor to treat a specific protein. The future will define indications for such drugs by tumor kinase profiles instead of tumor entities. Gleevec, inhibiting the BCR-ABL tyrosine kinase; Iressa, inhibiting the EGF-receptor tyrosine kinase, Herceptin, inhibiting the Her2 / neu tyrosine kinase and PTK787 / ZK222584, inhibiting the VEGF-receptor tyrosine kinase will be discussed as representatives of selective tyrosine kinase inhibitors whereas ZD6474 and SU6668 will be discussed as representatives of multitarget tyrosine kinase inhibitors.

Keywords: tyrosine kinases; receptor tyrosine kinase; anti cancer; vegf-receptor; egf-receptor

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389450033346885

Publication date: 2003-02-01

• Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Drevs J. ;  Medinger M. ;  Schmidt-Gersbach C. ;  Weber R. ;  Unger C.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers